Welcome to LookChem.com Sign In|Join Free

CAS

  • or

172505-78-1

Post Buying Request

172505-78-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

172505-78-1 Usage

Chemical structure

The compound has a complex structure that includes a thiazole ring, a thiourea functional group, a nitrophenyl group, and an ethyl chain.

Biological activities

Thioureas are known for their diverse biological activities, which may include antimicrobial, antiviral, and antitumor properties.

Thiazole ring

The presence of the thiazole ring suggests potential biological activity related to this structural motif.

Potential applications

The compound may have potential applications in the development of pharmaceuticals or agrochemicals.

Further research

Further research would be needed to fully understand the properties and potential uses of this compound.

Nitro group

The presence of a nitro group (-NO2) in the compound may contribute to its reactivity and potential applications.

Ethyl chain

The ethyl chain (-CH2CH3) in the compound may influence its solubility and other physical properties.

Chemical reactivity

The compound may exhibit reactivity due to the presence of the nitro group and the thiourea functional group.

Molecular weight

The molecular weight of the compound is approximately 238.28 g/mol.

Structural isomers

The compound may have structural isomers, which could have different properties and applications.

Stability

The stability of the compound under various conditions (e.g., temperature, pH, etc.) would need to be investigated.

Synthesis

The synthesis of the compound may involve multiple steps, including the formation of the thiazole ring and the attachment of the nitrophenyl and ethyl groups.

Purity

The purity of the synthesized compound would need to be confirmed, as impurities could affect its properties and potential applications.

Characterization

Techniques such as NMR, IR, and mass spectrometry would be used to characterize the compound and confirm its structure.

Check Digit Verification of cas no

The CAS Registry Mumber 172505-78-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,5,0 and 5 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 172505-78:
(8*1)+(7*7)+(6*2)+(5*5)+(4*0)+(3*5)+(2*7)+(1*8)=131
131 % 10 = 1
So 172505-78-1 is a valid CAS Registry Number.

172505-78-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[2-(2-nitrophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea

1.2 Other means of identification

Product number -
Other names PETT Analog 10

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:172505-78-1 SDS

172505-78-1Downstream Products

172505-78-1Relevant articles and documents

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

Bell,Cantrell,Hogberg,Jaskunas,Johansson,Jordan,Kinnick,Lind,Morin Jr.,Noreen,Oberg,Palkowitz,Parrish,Pranc,Sahlberg,Ternansky,Vasileff,Vrang,West,et al.

, p. 4929 - 4936 (2007/10/03)

A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 172505-78-1